WO2005090407A8 - Human anti-epidermal growth factor receptor antibody - Google Patents

Human anti-epidermal growth factor receptor antibody

Info

Publication number
WO2005090407A8
WO2005090407A8 PCT/US2005/009583 US2005009583W WO2005090407A8 WO 2005090407 A8 WO2005090407 A8 WO 2005090407A8 US 2005009583 W US2005009583 W US 2005009583W WO 2005090407 A8 WO2005090407 A8 WO 2005090407A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
egfr
growth factor
factor receptor
epidermal growth
Prior art date
Application number
PCT/US2005/009583
Other languages
French (fr)
Other versions
WO2005090407A1 (en
Inventor
Meilin Liu
Zhenping Zhu
Original Assignee
Imclone Systems Inc
Meilin Liu
Zhenping Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200580015481.2A priority Critical patent/CN101233155B/en
Priority to ES05732383T priority patent/ES2387809T3/en
Priority to SI200531573T priority patent/SI1735348T1/en
Priority to PL05732383T priority patent/PL1735348T3/en
Priority to JP2007504185A priority patent/JP4734319B2/en
Priority to US10/593,804 priority patent/US7598350B2/en
Priority to MXPA06010715A priority patent/MXPA06010715A/en
Priority to CA2560305A priority patent/CA2560305C/en
Application filed by Imclone Systems Inc, Meilin Liu, Zhenping Zhu filed Critical Imclone Systems Inc
Priority to DK05732383.4T priority patent/DK1735348T3/en
Priority to EP05732383A priority patent/EP1735348B1/en
Priority to AU2005224267A priority patent/AU2005224267B2/en
Publication of WO2005090407A1 publication Critical patent/WO2005090407A1/en
Publication of WO2005090407A8 publication Critical patent/WO2005090407A8/en
Priority to CY2016016C priority patent/CY2016016I2/en
Priority to LU93093C priority patent/LU93093I2/en
Priority to LTPA2016020C priority patent/LTC1735348I2/en
Priority to NL300819C priority patent/NL300819I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides a fully human antibody that binds human EGFR with affinity comparable to or higher than IMC-C225, and that neutralizes activation of EGFR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chains antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells and animals that encode and express these antibodies. The invention further provides a method for neutralizing activation of EGFR, treating in a mammal with neoplastic growth and non-cancerous hyperproliferative diseases using the antibodies alone or in combination with other agents.
PCT/US2005/009583 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody WO2005090407A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DK05732383.4T DK1735348T3 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
ES05732383T ES2387809T3 (en) 2004-03-19 2005-03-21 Antibody to human epidermal growth factor receptor
EP05732383A EP1735348B1 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
JP2007504185A JP4734319B2 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
US10/593,804 US7598350B2 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
MXPA06010715A MXPA06010715A (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody.
CA2560305A CA2560305C (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
CN200580015481.2A CN101233155B (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
SI200531573T SI1735348T1 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
PL05732383T PL1735348T3 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
AU2005224267A AU2005224267B2 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody
CY2016016C CY2016016I2 (en) 2004-03-19 2016-05-20 HUMAN ANTI-DETERMINAL GROWTH FACTOR RECEPTOR ANTIBODY
LU93093C LU93093I2 (en) 2004-03-19 2016-05-31 NECITUMUMAB AND ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES (PORTRAZZA)
LTPA2016020C LTC1735348I2 (en) 2004-03-19 2016-06-01 Antibody against Human Epidermal Growth Factor Receptor
NL300819C NL300819I2 (en) 2004-03-19 2016-06-14

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55455504P 2004-03-19 2004-03-19
US60/554,555 2004-03-19
US62426404P 2004-11-02 2004-11-02
US60/624,264 2004-11-02

Publications (2)

Publication Number Publication Date
WO2005090407A1 WO2005090407A1 (en) 2005-09-29
WO2005090407A8 true WO2005090407A8 (en) 2005-12-01

Family

ID=34964896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009583 WO2005090407A1 (en) 2004-03-19 2005-03-21 Human anti-epidermal growth factor receptor antibody

Country Status (18)

Country Link
US (1) US7598350B2 (en)
EP (2) EP1735348B1 (en)
JP (1) JP4734319B2 (en)
CN (1) CN103007279B (en)
AU (1) AU2005224267B2 (en)
CA (1) CA2560305C (en)
CY (2) CY1113037T1 (en)
DK (1) DK1735348T3 (en)
ES (1) ES2387809T3 (en)
HU (1) HUS000495I2 (en)
LT (1) LTC1735348I2 (en)
LU (1) LU93093I2 (en)
MX (1) MXPA06010715A (en)
NL (1) NL300819I2 (en)
PL (1) PL1735348T3 (en)
PT (1) PT1735348E (en)
RU (1) RU2402569C2 (en)
WO (1) WO2005090407A1 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CA2373815A1 (en) * 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
JP2004527456A (en) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Treatment of hyperproliferative diseases with EGF receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
CN102584997A (en) * 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1900753B1 (en) * 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
CN101058609B (en) * 2006-05-26 2011-04-13 神州细胞工程有限公司 Human antibody and expression thereof
AU2007260769A1 (en) * 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
US20090280503A1 (en) * 2006-09-15 2009-11-12 James Fiore Method for detecting and treating skin disorders
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2009067242A2 (en) * 2007-11-20 2009-05-28 Imclone Llc Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
EP2769991B1 (en) * 2008-01-03 2018-08-22 The Scripps Research Institute Antibody targeting through a modular recognition domain
EP2247301B1 (en) * 2008-02-20 2014-06-11 Arizona Biomedical Research Commission Use of therapeutic fusion peptides for the treatment and prevention of cancer
MX2011001445A (en) 2008-08-05 2011-04-05 Toray Industries Cancer detection method.
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
JP5851842B2 (en) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. Modified antibody composition and methods of making and using the same
KR101108642B1 (en) * 2009-09-29 2012-02-09 주식회사 녹십자 Antibodies specifically binding to the epidermal growth factor receptor
CN101875696B (en) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 Antibody, and preparation method and application thereof
CN101704891B (en) 2009-11-11 2011-11-09 中国人民解放军军事医学科学院生物工程研究所 Antibody for epidermal growth factor receptor, encoding gene thereof and application thereof
CN101875695B (en) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 Antibody, and coding gene and application thereof
SI2513147T1 (en) * 2009-12-18 2016-11-30 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries Pharmaceutical composition for treating and/or preventing cancer
PT2532365T (en) 2010-02-04 2016-07-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
MX340015B (en) 2010-02-04 2016-06-22 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
RU2624029C2 (en) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Drugs for cancer treatment and/or prevention
KR101871704B1 (en) 2010-02-04 2018-06-27 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
CN103201293B (en) 2010-09-08 2016-04-27 哈洛齐梅公司 The method of assessment and qualification or development condition active therapeutic protein
KR101273918B1 (en) 2010-09-17 2013-06-13 강원대학교산학협력단 A human anti-epidermal growth factor receptor Fab antibody and a pharmaceutical composition for treating tumor comprising the same
EP2627674A4 (en) 2010-10-12 2014-04-30 Arizona Biomedical Res Commission Egfr-based peptides
EP2632490A4 (en) * 2010-10-29 2014-10-22 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
ES2704038T3 (en) 2011-05-24 2019-03-13 Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
EP2740793B1 (en) 2011-08-04 2017-11-29 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
KR101980554B1 (en) 2011-08-04 2019-05-21 도레이 카부시키가이샤 Cancer treatment and/or prevention drug composition
ES2672695T3 (en) 2011-08-04 2018-06-15 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prophylaxis of cancer
WO2013018885A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Method for detecting pancreatic cancer
PT2740796T (en) 2011-08-04 2017-07-26 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
BR112014002614B1 (en) 2011-08-04 2022-09-20 Toray Industries, Inc ANTIBODY OR A FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION, USE OF AN ANTIBODY, USE OF A PHARMACEUTICAL COMPOSITION AND USE OF A PHARMACEUTICAL COMBINATION
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
IN2014KN01715A (en) 2012-02-21 2015-10-23 Toray Industries
WO2013125636A1 (en) 2012-02-21 2013-08-29 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of cancer
MX363136B (en) 2012-02-21 2019-03-12 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) 2012-02-21 2018-10-24 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
PL2832366T3 (en) 2012-03-30 2018-04-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
US9944707B2 (en) 2012-05-17 2018-04-17 Sorrento Therapeutics, Inc. Antibodies that bind epidermal growth factor receptor (EGFR)
JP6103832B2 (en) 2012-06-25 2017-03-29 Hoya株式会社 EGFR binding peptide
RU2646466C2 (en) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Method for cancer detection
JP6244912B2 (en) 2012-07-19 2017-12-13 東レ株式会社 Cancer detection method
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014028221A1 (en) 2012-07-31 2014-02-20 Crown Bioscience, Inc. Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
CN102993305B (en) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
EP2985292A4 (en) * 2013-04-07 2016-12-21 Genrix(Shanghai) Biopharmacertical Co Ltd Epidermal growth factor receptor antibody
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN105764924A (en) 2013-09-12 2016-07-13 哈洛齐梅公司 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
EP3083685A2 (en) 2013-12-20 2016-10-26 Intervet International B.V. Canine antibodies with modified ch2-ch3 sequences
BR112016014830A2 (en) 2013-12-23 2017-09-19 Bayer Pharma AG ANTIBODY DRUG CONJUGATES (ADCS) WITH KSP INHIBITORS
CN106459211B (en) 2014-03-03 2020-03-10 中央研究院 Bifunctional antibodies and uses thereof
US20170226216A1 (en) * 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
CN105315371B (en) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 Anti-human IL-17 monoclonal antibodies
WO2016161440A2 (en) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3
TW201703769A (en) 2015-05-08 2017-02-01 美國禮來大藥廠 Combination therapy for cancer
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
PE20180452A1 (en) 2015-06-23 2018-03-05 Bayer Pharma AG SITE-SPECIFIC HOMOGENEOUS CONJUGATES WITH KSP INHIBITORS
TW201716439A (en) 2015-07-20 2017-05-16 美國禮來大藥廠 HER3 antibodies
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
JP7251981B2 (en) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト Prodrugs of Cytotoxic Active Agents with Enzymatic Cleavage Groups
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
EP3515940A1 (en) * 2016-09-26 2019-07-31 ImClone LLC Combination therapy for cancer
JP7066714B2 (en) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト Antibody drug conjugate (ADC) with an enzymatically cleavable group
US20190351066A1 (en) 2016-12-21 2019-11-21 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7030811B2 (en) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Specific antibody with KSP inhibitor-drug conjugate (ADC)
JP7072792B2 (en) * 2017-12-11 2022-05-23 国立大学法人神戸大学 Bispecific antibody
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
CN113260379B (en) * 2018-12-21 2022-09-02 浙江时迈药业有限公司 Protease cleavable bispecific antibodies and uses thereof
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN117186219A (en) * 2020-04-17 2023-12-08 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN116782932A (en) * 2020-08-05 2023-09-19 俄亥俄州国家创新基金会 Adapter polypeptides and methods of use thereof
JP2023545681A (en) * 2020-09-30 2023-10-31 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ Chimeric antigen receptor targeting EGFR
WO2022140670A2 (en) * 2020-12-23 2022-06-30 Phenomic Ai Anti-activin antibodies and methods of using the same

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4186567A (en) * 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US4510924A (en) * 1980-07-10 1985-04-16 Yale-New Haven Hospital, Inc. Brachytherapy devices and methods employing americium-241
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4763642A (en) * 1986-04-07 1988-08-16 Horowitz Bruce S Intracavitational brachytherapy
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (en) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド IL-2 receptor-specific chimeric antibody
ES2070172T3 (en) 1988-04-16 1995-06-01 Celltech Ltd PROCEDURE FOR PRODUCING PROTEINS BY RECOMBINANT DNA.
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0481000B1 (en) * 1989-07-06 1999-05-12 The Regents Of The University Of California Receptors for fibroblast growth factors
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
WO1991016051A1 (en) 1990-04-16 1991-10-31 Rhône-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1362868A3 (en) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5550114A (en) * 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
CZ288955B6 (en) * 1994-02-23 2001-10-17 Pfizer Inc. Substituted quinazoline derivatives, their use and pharmaceutical preparations based thereon
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
RU2170257C2 (en) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Anti-egfr single-chain fv, chimeric anti-egfr antibody and method of its preparing, pharmaceutical composition for treatment of patients with tumors, agent for diagnosis of localization and estimation of tumor growth
JP3249007B2 (en) * 1994-03-17 2002-01-21 富士通株式会社 Semiconductor device, characteristic evaluation method and design method thereof
US5656655A (en) * 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1997027199A1 (en) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
WO1997046684A1 (en) * 1996-06-06 1997-12-11 University Of Massachusetts Non-activated receptor complex proteins and uses thereof
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CA2344169C (en) 1998-09-29 2011-07-19 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
BR9915487A (en) 1998-11-19 2001-07-31 Warner Lambert Co N- [4- (3-chloro-4-fluoro-phenylamino) - 7 - (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide, an irreversible inhibitor of tyrosine kinases
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
CA2373815A1 (en) * 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DK1054018T3 (en) 1999-05-18 2009-05-18 Dyax Corp Fab fragment libraries and method of using them
DE60042693D1 (en) * 1999-08-27 2009-09-17 Genentech Inc DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
JP2004527456A (en) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Treatment of hyperproliferative diseases with EGF receptor antagonists
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002087618A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DE10163459A1 (en) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilized preparation containing antibodies to EGF receptor
JP2005518789A (en) * 2002-01-28 2005-06-30 メダレックス， インク． Human monoclonal antibody against prostate specific membrane antigen (PSMA)
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20050176633A1 (en) * 2002-03-08 2005-08-11 Axel Ullrich Use of egfr transactivation inhibitors in human cancer
ATE422894T1 (en) * 2002-03-21 2009-03-15 Cayman Chem Co PROSTAGLANDIN F2 ALPHA ANALOGA IN COMBINATION WITH AN ANTIMICROBIAL AGENT FOR THE TREATMENT OF GLAUCOMA
AU2003241898A1 (en) * 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
AU2003251791B2 (en) * 2002-07-03 2009-07-23 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
EP1549344B1 (en) * 2002-10-10 2015-01-07 Merck Patent GmbH Pharmaceutical compositions directed to erb-b1 receptors
US20060228355A1 (en) * 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10355904A1 (en) * 2003-11-29 2005-06-30 Merck Patent Gmbh Solid forms of anti-EGFR antibodies
AU2005211890B2 (en) * 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
JP5835204B2 (en) 2012-12-20 2015-12-24 信越化学工業株式会社 Resist material and pattern forming method using the same

Also Published As

Publication number Publication date
EP1735348A1 (en) 2006-12-27
LU93093I2 (en) 2016-08-01
CN103007279A (en) 2013-04-03
RU2006137060A (en) 2008-04-27
JP2008500815A (en) 2008-01-17
RU2402569C2 (en) 2010-10-27
JP4734319B2 (en) 2011-07-27
HUS000495I2 (en) 2021-03-29
CY1113037T1 (en) 2016-04-13
CA2560305A1 (en) 2005-09-29
EP2332990A1 (en) 2011-06-15
US20070264253A1 (en) 2007-11-15
MXPA06010715A (en) 2007-05-23
AU2005224267A1 (en) 2005-09-29
NL300819I2 (en) 2016-07-21
LTC1735348I2 (en) 2017-11-10
DK1735348T3 (en) 2012-07-16
AU2005224267B2 (en) 2011-07-21
CY2016016I1 (en) 2016-12-14
ES2387809T3 (en) 2012-10-02
CN103007279B (en) 2017-01-11
EP1735348B1 (en) 2012-06-20
CY2016016I2 (en) 2016-12-14
HUS1600030I1 (en) 2016-07-28
US7598350B2 (en) 2009-10-06
PL1735348T3 (en) 2012-11-30
CA2560305C (en) 2016-07-05
PT1735348E (en) 2012-07-24
WO2005090407A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2005090407A8 (en) Human anti-epidermal growth factor receptor antibody
WO2003075840A3 (en) Human antibodies specific to kdr and uses thereof
DK1565489T3 (en) Internalizing antibodies specific for the RAAG10 cell surface target
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
NZ592215A (en) c-MET ANTIBODIES
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
ATE530195T1 (en) BISPECIFIC SINGLE CHAIN FV ANTIBODIES MOLECULES AND METHODS OF APPLICATION THEREOF
WO2009000098A3 (en) Sequence based engineering and optimization of single chain antibodies
EP3202786A3 (en) Sequence based engineering and optimization of single chain antibodies
ATE476992T1 (en) NEUTRALIZABLE EPITOPE OF HGF AND NEUTRALIZING ANTIBODIES BINDING TO IT
SG138469A1 (en) Antibodies to insulin-like growth factor i receptor
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
NZ596381A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2008112640A3 (en) Construction and use of a functionally human antibody library with maximized repertoire diversity
NZ594682A (en) Fully human antibodies specific to cadm1
JP2019528694A5 (en)
MX2022000174A (en) Monoclonal antibodies that bind egfrviii and their use.
WO2008085551A3 (en) Smallpox monoclonal antibody
WO2005114107A8 (en) Use of a monoclonal antibody that specifically binds stem cells
TH83706A (en) Antit-5T4 Antibody that is humane and conjugated of Ant-5T4. Antibodies / Calicamine
TH83706B (en) Antit-5T4 Antibody that is humane and conjugated of Ant-5T4. Antibodies / Calicamine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010715

Country of ref document: MX

Ref document number: 383490

Country of ref document: PL

Ref document number: 2007504185

Country of ref document: JP

Ref document number: 2560305

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005732383

Country of ref document: EP

Ref document number: 2006137060

Country of ref document: RU

Ref document number: 2005224267

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005224267

Country of ref document: AU

Date of ref document: 20050321

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005224267

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580015481.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005732383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10593804

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10593804

Country of ref document: US